A combination phase I study of biweekly docetaxel and 5’-DFUR in patients with unresectable or recurrent gastric cancer No significant financial relationships to disclose. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback